Abstract
No public abstract is available from the verified source records.
Doris Lechner, Franz Bucar
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis
10.1164/rccm.167.4.603 · 2003
Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure–activity relationship study
10.3727/000000003108747983 · 2003
Flavonoid inhibitors as novel antimycobacterial agents targeting Rv0636, a putative dehydratase enzyme involved in Mycobacterium tuberculosis fatty acid synthase II
10.1099/mic.0.2007/009936-0 · 2007
Antimycobacterial plant terpenoids
10.1055/s-2001-18365 · 2001
Isoniazid accumulation in Mycobacterium smegmatis is modulated by proton motive force-driven and ATP-dependent extrusion systems
10.1006/bbrc.1999.0357 · 1999
The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol
10.1111/j.1365-2958.2005.04510.x · 2005
Role of mycobacterial efflux transporters in drug resistance: An unresolved question
10.1111/j.1574-6976.2005.00002.x · 2006
Identification and validation of novel drug targets in tuberculosis
10.2174/1381612043383223 · 2004
Unresolved referenced work
1999
Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents
10.1046/j.1469-0691.2000.00149.x · 2000
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth
10.1086/510247 · 2007
The AhpC and AhpD antioxidant defense system of Mycobacterium tuberculosis
10.1074/jbc.m001001200 · 2000
Inhibiting activities of the secondary metabolites of Phlomis brunneogaleata against parasitic Protozoa and plasmodial enoyl-ACP reductase, a crucial enzyme in fatty acid biosynthesis
10.1055/s-2004-827200 · 2004
InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II
10.1099/00221287-146-2-289 · 2000
Agylcone flavonoids in experimental chemotherapy
1949
mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis
10.1128/aac.49.11.4775-4777.2005 · 2005
Flavonoids as antioxidants
10.1021/np9904509 · 2000
A method of treatment with flavonoids for overcoming acquired or inherent resistance to chemotherapeutic compounds
2007
TB drug discovery: Addressing issues of persistence and resistance
10.1016/j.tube.2003.08.019 · 2004
Antioxidative and antiradical properties of plant phenolics
10.1515/znc-2005-11-1204 · 2005
Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin
10.1016/j.bcp.2005.03.001 · 2005
Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis
10.1128/aac.46.9.2804-2810.2002 · 2002
Unresolved referenced work
Kept as external metadata until matched
Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant
10.1021/bi051967o · 2006
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
10.1038/79558 · 2000
Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene
10.1128/jb.186.13.4051-4055.2004 · 2004
No additional external references are available.